vs

Side-by-side financial comparison of First Guaranty Bancshares, Inc. (FGBI) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $22.3M, roughly 1.6× First Guaranty Bancshares, Inc.). First Guaranty Bancshares, Inc. runs the higher net margin — 12.1% vs -304.2%, a 316.3% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -10.9%). First Guaranty Bancshares, Inc. produced more free cash flow last quarter ($-10.0M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -4.0%).

First Citizens Bancshares, Inc. is a bank holding company based in Raleigh, North Carolina and one of the largest banks in the United States. Its primary subsidiary is First Citizens Bank, which operates over 500 branches in 23 states. A second subsidiary is Silicon Valley Bank, which operates 39 offices in 15 states.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FGBI vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.6× larger
RXRX
$35.5M
$22.3M
FGBI
Growing faster (revenue YoY)
RXRX
RXRX
+692.6% gap
RXRX
681.7%
-10.9%
FGBI
Higher net margin
FGBI
FGBI
316.3% more per $
FGBI
12.1%
-304.2%
RXRX
More free cash flow
FGBI
FGBI
$37.3M more FCF
FGBI
$-10.0M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-4.0%
FGBI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FGBI
FGBI
RXRX
RXRX
Revenue
$22.3M
$35.5M
Net Profit
$2.5M
$-108.1M
Gross Margin
59.8%
Operating Margin
14.4%
-304.8%
Net Margin
12.1%
-304.2%
Revenue YoY
-10.9%
681.7%
Net Profit YoY
142.6%
39.6%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FGBI
FGBI
RXRX
RXRX
Q4 25
$22.3M
$35.5M
Q3 25
$24.1M
$5.2M
Q2 25
$24.4M
$19.2M
Q1 25
$24.6M
$14.7M
Q4 24
$25.1M
$4.5M
Q3 24
$27.1M
$26.1M
Q2 24
$36.8M
$14.4M
Q1 24
$24.2M
$13.8M
Net Profit
FGBI
FGBI
RXRX
RXRX
Q4 25
$2.5M
$-108.1M
Q3 25
$-45.0M
$-162.3M
Q2 25
$-7.3M
$-171.9M
Q1 25
$-6.2M
$-202.5M
Q4 24
$1.0M
$-178.9M
Q3 24
$1.9M
$-95.8M
Q2 24
$7.2M
$-97.5M
Q1 24
$2.3M
$-91.4M
Gross Margin
FGBI
FGBI
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
FGBI
FGBI
RXRX
RXRX
Q4 25
14.4%
-304.8%
Q3 25
-224.1%
-3327.6%
Q2 25
-38.9%
-916.8%
Q1 25
-32.5%
-1297.9%
Q4 24
4.7%
-4042.4%
Q3 24
9.2%
-377.1%
Q2 24
25.4%
-697.4%
Q1 24
12.3%
-698.4%
Net Margin
FGBI
FGBI
RXRX
RXRX
Q4 25
12.1%
-304.2%
Q3 25
-186.7%
-3135.3%
Q2 25
-29.9%
-894.2%
Q1 25
-25.1%
-1373.3%
Q4 24
4.0%
-3935.5%
Q3 24
7.1%
-367.5%
Q2 24
19.6%
-676.6%
Q1 24
9.5%
-662.4%
EPS (diluted)
FGBI
FGBI
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FGBI
FGBI
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$179.0M
$9.6M
Stockholders' EquityBook value
$226.2M
$1.1B
Total Assets
$4.1B
$1.5B
Debt / EquityLower = less leverage
0.79×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FGBI
FGBI
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
FGBI
FGBI
RXRX
RXRX
Q4 25
$179.0M
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$194.9M
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
FGBI
FGBI
RXRX
RXRX
Q4 25
$226.2M
$1.1B
Q3 25
$221.1M
$1.0B
Q2 25
$263.1M
$919.1M
Q1 25
$251.4M
$933.9M
Q4 24
$255.0M
$1.0B
Q3 24
$256.4M
$524.6M
Q2 24
$255.1M
$584.4M
Q1 24
$250.3M
$401.2M
Total Assets
FGBI
FGBI
RXRX
RXRX
Q4 25
$4.1B
$1.5B
Q3 25
$3.8B
$1.4B
Q2 25
$4.0B
$1.3B
Q1 25
$3.8B
$1.3B
Q4 24
$4.0B
$1.4B
Q3 24
$3.9B
$726.5M
Q2 24
$3.6B
$775.9M
Q1 24
$3.6B
$557.8M
Debt / Equity
FGBI
FGBI
RXRX
RXRX
Q4 25
0.79×
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.76×
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FGBI
FGBI
RXRX
RXRX
Operating Cash FlowLast quarter
$-8.3M
$-46.1M
Free Cash FlowOCF − Capex
$-10.0M
$-47.3M
FCF MarginFCF / Revenue
-44.6%
-133.1%
Capex IntensityCapex / Revenue
7.6%
3.5%
Cash ConversionOCF / Net Profit
-3.38×
TTM Free Cash FlowTrailing 4 quarters
$5.4M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FGBI
FGBI
RXRX
RXRX
Q4 25
$-8.3M
$-46.1M
Q3 25
$29.4M
$-117.4M
Q2 25
$-18.3M
$-76.4M
Q1 25
$5.4M
$-132.0M
Q4 24
$33.7M
$-115.4M
Q3 24
$4.9M
$-59.2M
Q2 24
$7.9M
$-82.2M
Q1 24
$2.0M
$-102.3M
Free Cash Flow
FGBI
FGBI
RXRX
RXRX
Q4 25
$-10.0M
$-47.3M
Q3 25
$28.7M
$-117.6M
Q2 25
$-18.6M
$-79.6M
Q1 25
$5.2M
$-133.8M
Q4 24
$30.7M
$-116.7M
Q3 24
$4.7M
$-63.8M
Q2 24
$6.6M
$-83.4M
Q1 24
$396.0K
$-109.0M
FCF Margin
FGBI
FGBI
RXRX
RXRX
Q4 25
-44.6%
-133.1%
Q3 25
119.3%
-2272.5%
Q2 25
-76.2%
-413.9%
Q1 25
21.1%
-907.4%
Q4 24
122.4%
-2567.7%
Q3 24
17.4%
-244.6%
Q2 24
18.0%
-578.5%
Q1 24
1.6%
-789.9%
Capex Intensity
FGBI
FGBI
RXRX
RXRX
Q4 25
7.6%
3.5%
Q3 25
2.9%
4.7%
Q2 25
1.1%
16.4%
Q1 25
0.8%
12.4%
Q4 24
12.1%
28.6%
Q3 24
0.5%
17.5%
Q2 24
3.5%
8.2%
Q1 24
6.6%
48.2%
Cash Conversion
FGBI
FGBI
RXRX
RXRX
Q4 25
-3.38×
Q3 25
Q2 25
Q1 25
Q4 24
33.40×
Q3 24
2.52×
Q2 24
1.10×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons